• Markets
  • icon
  • Companies
MSB · ASX

Mesoblast Limited (ASX:MSB)

AU$0.76

 -0.01 (-1.29%)
ASX:Live
19/04/2024 04:10:42 PM
HALO Small HALO Ords GROWTH AUS Fakey Shakey - Short EMA 125 Breakup +2
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

MSB Overview

MSB Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Very Strong

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About MSB

Telephone

Address

Description

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

MSB Price Chart

Key Stats

Market Cap

AU$884.88M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.25 - 1.35

Trade Value (12mth)

US$501,194.00

1 week

-11.05%

1 month

128.36%

YTD

150.82%

1 year

-18.5%

All time high

9.42389

Key Fundamentals

EPS 3 yr Growth

-28.700%

EBITDA Margin

-915.70%

Operating Cashflow

-$69m

Free Cash Flow Return

-11.60%

ROIC

-13.70%

Interest Coverage

-3.40

Quick Ratio

1.90

Other Data

Shares on Issue (Fully Dilluted)

851m

HALO Sector

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

USD

Short Sell (% of issue)

3.07

MSB Announcements

Latest Announcements

Date Announcements

16 April 24

Notification regarding unquoted securities - MSB

×

Notification regarding unquoted securities - MSB

16 April 24

Application for quotation of securities - MSB

×

Application for quotation of securities - MSB

16 April 24

Appendix 3Y for Jane Bell

×

Appendix 3Y for Jane Bell

15 April 24

Notification of cessation of securities - MSB

×

Notification of cessation of securities - MSB

09 April 24

Change in substantial holding

×

Change in substantial holding

02 April 24

Change in substantial holding

×

Change in substantial holding

26 March 24

Cleansing Notice

×

Cleansing Notice

26 March 24

Pause in Trading

×

Pause in Trading

26 March 24

FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA

×

FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA

22 March 24

Application for quotation of securities - MSB

×

Application for quotation of securities - MSB

20 March 24

Proposed issue of securities - MSB

×

Proposed issue of securities - MSB

20 March 24

Change in substantial holding

×

Change in substantial holding

19 March 24

Cleansing Notice

×

Cleansing Notice

18 March 24

Appendix 2A

×

Appendix 2A

14 March 24

Mesoblast Completes Placement and Entitlement Offer

×

Mesoblast Completes Placement and Entitlement Offer

14 March 24

Proposed issue of securities - MSB

×

Proposed issue of securities - MSB

11 March 24

FDA Supports Accelerated Approval Pathway for Heart Failure

×

FDA Supports Accelerated Approval Pathway for Heart Failure

29 February 24

Half Year Report and Accounts (including Appendix 4D)

×

Half Year Report and Accounts (including Appendix 4D)

29 February 24

Half Year Financial Results Presentation

×

Half Year Financial Results Presentation

29 February 24

MSB Q2 Financial Results and Operational Highlights

×

MSB Q2 Financial Results and Operational Highlights

26 February 24

Mesoblast 2024 Half Year Financial Results Webcast

×

Mesoblast 2024 Half Year Financial Results Webcast

15 February 24

FDA Grants Orphan Drug Designation for Revascor

×

FDA Grants Orphan Drug Designation for Revascor

31 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

19 January 24

FDA Grants Rare Pediatric Disease Designation for Revascor

×

FDA Grants Rare Pediatric Disease Designation for Revascor

15 January 24

Notification of cessation of securities - MSB

×

Notification of cessation of securities - MSB

MSB Fundamentals

Per Share Records

Historical data

Forecasted data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.16 -0.14 -0.11 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.16 -0.14 -0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.8 13.8 25.4 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.15 -0.12 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.18 -0.11 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.4 22.1 34.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -12.1 -25.1 -12.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.90 0.76 0.58 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 -0.13 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 102.4 -9,660.3 30.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 605 649 779 Lock Lock Lock
Basic m Lock Lock Lock Lock 605 649 779 Lock Lock Lock

Financial Records

Historical data

Forecasted data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 7 10 8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -76.5 37.4 -26.5 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 84 60 53 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -25 -21 -20 Lock Lock Lock
     Growth % Lock Lock Lock Lock -501.0 18.7 1.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -340.1 -201.2 -269.7 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 440 301 370 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -105 -76 -69 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.0 27.4 9.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,411.1 -746.2 -915.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 4 4 4 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -109 -81 -73 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.6 26.2 9.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,468.4 -789.1 -970.5 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -100 -92 -86 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 0 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -99 -91 -82 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.8 7.6 10.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,329.2 -894.6 -1,091.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -107 -72 -69 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 2 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -2 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 114 -4 81 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -108 -72 -70 Lock Lock Lock
     Growth % Lock Lock Lock Lock -85.3 33.5 3.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -14.6 -7.1 -9.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 137 60 71 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 825 750 669 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 50 99 106 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -31 46 45 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 243 253 168 Lock Lock Lock
Equity $m Lock Lock Lock Lock 578 524 507 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 631 596 608 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.0 -5.6 2.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -12.0 -12.2 -12.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -17.1 -17.4 -16.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -15.8 -12.4 -12.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -15.3 -14.8 -13.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -16.5 -11.6 -11.6 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -6.6 -4.4 -3.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.3 -0.6 -0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -5.4 8.9 8.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.6 1.4 1.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.6 1.4 1.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 92.3 86.6 87.3 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -113.2 -139.9 -165.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.3 2.2 1.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.5 0.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 261.9 238.4 271.4 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,340.2 -896.9 -1,141.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -12.1 -12.2 -12.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -12.0 -12.2 -12.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 1.4 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -17.1 -17.4 -16.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -17.1 -17.4 -16.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 160.0 166.6 276.8 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 160.0 166.6 276.8 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 259.5 256.8 282.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -99.6 -90.2 -5.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

3.07%

Value ($M)

29

Prior Change

-0.10%

7 Day Change

0.10%

1 Month Change

0.60%

3 Month Change

0.50%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

MSB Shortsell

Frequently Asked Questions

The current share price of Mesoblast Limited (MSB:ASX) is AU$0.76.
The 52-week high share price for Mesoblast Limited (MSB:ASX) is AU$1.35.
The 52-week low share price for Mesoblast Limited (MSB:ASX)? is AU$0.25.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) has a franking level of 0%.
Mesoblast Limited (MSB:ASX) is classified in the Healthcare.
The current P/E ratio for Mesoblast Limited (MSB:ASX) is .